alexa Use of Lorcaserin, A 5HT2C Agonist, In the Management o
ISSN: 2167-0943

Journal of Metabolic Syndrome
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Use of Lorcaserin, A 5HT2C Agonist, In the Management of OlanzapineInduced Weight Gain

Charles Nguyen1, Amanda Suzuki2 and Kevin Bera3*
1UC Irvine Medical Center, USA
2Department of Psychiatry at UC Irvine, USA
3University of Southern California, USA
Corresponding Author : Kevin Rimal Bera
University of Southern California
41 Exploration Irvine, CA 92618, USA
Tel: +1-949-933-0380
E-mail: [email protected]
Received: October 26, 2015; Accepted: November 14, 2015; Published: November 16, 2015
Citation: Nguyen C, Suzuki A, Bera K (2015) Use of Lorcaserin, A 5HT2C Agonist, In the Management of Olanzapine-Induced Weight Gain. J Metabolic Synd 4:190. doi:10.4172/2167-0943.1000190
Copyright: © 2015 Nguyen C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 

Abstract

 Abstract

Atypical antipsychotics are associated with weight gain, which compromise medication adherence and pose longterm health complications. These are two cases in which lorcaserin, a 5HT2C agonist, has been used to counteract olanzapine-induced weight gain in conjunction with a low carbohydrate diet. In Case 1, patient lost a significant amount of weight and reported decreased food cravings. In Case 2, patient showed initial response but was unable to maintain diet. Patient had significant weight gain and reported increased cravings after discontinuing lorcaserin. These cases demonstrate 5HT2C agonists’ potential for management of atypical antipsychotic-related weight gain.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords